Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colorectal Neoplasms | 29 | 2024 | 6942 | 2.930 |
Why?
|
Rectal Neoplasms | 11 | 2025 | 1182 | 2.110 |
Why?
|
Neoplasm, Residual | 5 | 2024 | 1009 | 2.060 |
Why?
|
Gastrointestinal Neoplasms | 7 | 2023 | 961 | 1.960 |
Why?
|
Colonic Neoplasms | 10 | 2024 | 2531 | 1.710 |
Why?
|
Medical Oncology | 12 | 2024 | 2339 | 1.010 |
Why?
|
Carcinoma, Pancreatic Ductal | 8 | 2024 | 1758 | 0.950 |
Why?
|
Neoadjuvant Therapy | 19 | 2025 | 2895 | 0.940 |
Why?
|
Pancreatic Neoplasms | 13 | 2024 | 5444 | 0.870 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 24 | 2025 | 11868 | 0.760 |
Why?
|
Anus Neoplasms | 5 | 2024 | 336 | 0.700 |
Why?
|
Standard of Care | 1 | 2024 | 567 | 0.690 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9373 | 0.670 |
Why?
|
DNA, Neoplasm | 3 | 2019 | 1742 | 0.640 |
Why?
|
Leucovorin | 11 | 2024 | 641 | 0.620 |
Why?
|
Fluorouracil | 13 | 2024 | 1648 | 0.550 |
Why?
|
Lymphopenia | 3 | 2025 | 297 | 0.540 |
Why?
|
Capacity Building | 1 | 2019 | 266 | 0.530 |
Why?
|
Neoplasms | 11 | 2024 | 22340 | 0.480 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1050 | 0.460 |
Why?
|
Adenocarcinoma | 6 | 2025 | 6364 | 0.460 |
Why?
|
Neoplasm Staging | 15 | 2024 | 11206 | 0.450 |
Why?
|
Stomach Neoplasms | 5 | 2021 | 1471 | 0.430 |
Why?
|
Mutation | 12 | 2024 | 30198 | 0.400 |
Why?
|
Faculty, Medical | 2 | 2021 | 1219 | 0.390 |
Why?
|
Neoplasm Metastasis | 6 | 2024 | 4893 | 0.390 |
Why?
|
Humans | 101 | 2025 | 765968 | 0.380 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 1761 | 0.370 |
Why?
|
Camptothecin | 4 | 2021 | 600 | 0.370 |
Why?
|
Antineoplastic Agents | 5 | 2024 | 13648 | 0.370 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2024 | 3655 | 0.360 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 618 | 0.360 |
Why?
|
Receptor, erbB-2 | 3 | 2024 | 2593 | 0.360 |
Why?
|
Prognosis | 15 | 2025 | 29922 | 0.350 |
Why?
|
Molecular Targeted Therapy | 3 | 2021 | 2822 | 0.340 |
Why?
|
DNA Damage | 1 | 2019 | 2457 | 0.320 |
Why?
|
Proto-Oncogene Proteins B-raf | 6 | 2023 | 2054 | 0.310 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1458 | 0.310 |
Why?
|
Gene Amplification | 4 | 2024 | 1091 | 0.290 |
Why?
|
Survival Rate | 12 | 2024 | 12795 | 0.280 |
Why?
|
Liver Neoplasms | 3 | 2018 | 4353 | 0.270 |
Why?
|
Pyrimidinones | 3 | 2024 | 384 | 0.270 |
Why?
|
Esophageal Neoplasms | 3 | 2021 | 1661 | 0.270 |
Why?
|
Bile Duct Neoplasms | 2 | 2024 | 626 | 0.270 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2024 | 4044 | 0.260 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2013 | 920 | 0.260 |
Why?
|
DNA Mismatch Repair | 3 | 2023 | 433 | 0.250 |
Why?
|
Middle Aged | 34 | 2025 | 223009 | 0.250 |
Why?
|
Quality of Life | 3 | 2023 | 13462 | 0.240 |
Why?
|
Pyridones | 3 | 2024 | 816 | 0.220 |
Why?
|
Lung Neoplasms | 4 | 2021 | 13451 | 0.210 |
Why?
|
Organoplatinum Compounds | 3 | 2021 | 404 | 0.210 |
Why?
|
Aged | 32 | 2025 | 171117 | 0.210 |
Why?
|
Immunotherapy | 4 | 2023 | 4752 | 0.210 |
Why?
|
bcl-X Protein | 1 | 2024 | 414 | 0.200 |
Why?
|
Carcinoembryonic Antigen | 1 | 2023 | 337 | 0.200 |
Why?
|
Male | 39 | 2025 | 363698 | 0.200 |
Why?
|
Female | 43 | 2025 | 396112 | 0.190 |
Why?
|
Aged, 80 and over | 12 | 2025 | 59489 | 0.190 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 222 | 0.190 |
Why?
|
Fund Raising | 1 | 2021 | 48 | 0.190 |
Why?
|
Treatment Outcome | 17 | 2024 | 65188 | 0.190 |
Why?
|
Prospective Studies | 10 | 2024 | 54802 | 0.180 |
Why?
|
Collagen Type I | 1 | 2024 | 615 | 0.180 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2024 | 3537 | 0.180 |
Why?
|
Receptors, Prostaglandin E, EP4 Subtype | 1 | 2020 | 44 | 0.170 |
Why?
|
Combined Modality Therapy | 6 | 2024 | 8529 | 0.170 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2021 | 5337 | 0.170 |
Why?
|
Hematologic Tests | 1 | 2021 | 239 | 0.170 |
Why?
|
Nurse Practitioners | 1 | 2022 | 272 | 0.160 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 784 | 0.160 |
Why?
|
Adult | 22 | 2025 | 223044 | 0.160 |
Why?
|
Radiodermatitis | 1 | 2019 | 58 | 0.160 |
Why?
|
Benzoates | 1 | 2020 | 213 | 0.150 |
Why?
|
Disease-Free Survival | 4 | 2022 | 6832 | 0.150 |
Why?
|
Aniline Compounds | 1 | 2024 | 1075 | 0.150 |
Why?
|
Cholangiocarcinoma | 1 | 2024 | 578 | 0.150 |
Why?
|
Biliary Tract Neoplasms | 1 | 2020 | 186 | 0.150 |
Why?
|
Neuroendocrine Tumors | 1 | 2025 | 654 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 120 | 0.150 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2022 | 521 | 0.150 |
Why?
|
Retrospective Studies | 20 | 2025 | 81514 | 0.140 |
Why?
|
Losartan | 1 | 2019 | 263 | 0.140 |
Why?
|
Albumins | 1 | 2020 | 577 | 0.140 |
Why?
|
Brazil | 1 | 2021 | 1248 | 0.140 |
Why?
|
Africa | 1 | 2019 | 725 | 0.140 |
Why?
|
Intestinal Neoplasms | 1 | 2019 | 313 | 0.140 |
Why?
|
Maytansine | 1 | 2017 | 87 | 0.130 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 735 | 0.130 |
Why?
|
Endonucleases | 1 | 2018 | 372 | 0.130 |
Why?
|
Autopsy | 1 | 2019 | 1011 | 0.120 |
Why?
|
Deoxycytidine | 1 | 2020 | 889 | 0.120 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 786 | 0.120 |
Why?
|
Emigrants and Immigrants | 1 | 2022 | 549 | 0.120 |
Why?
|
DNA Copy Number Variations | 1 | 2024 | 2045 | 0.120 |
Why?
|
Immunoconjugates | 1 | 2023 | 981 | 0.120 |
Why?
|
Off-Label Use | 1 | 2017 | 185 | 0.120 |
Why?
|
Radiotherapy | 1 | 2021 | 1494 | 0.120 |
Why?
|
Feasibility Studies | 2 | 2023 | 5302 | 0.120 |
Why?
|
Breast Neoplasms | 3 | 2019 | 21056 | 0.120 |
Why?
|
Gastrectomy | 1 | 2020 | 694 | 0.120 |
Why?
|
DNA Replication | 1 | 2021 | 1433 | 0.110 |
Why?
|
Practice Guidelines as Topic | 4 | 2020 | 7425 | 0.110 |
Why?
|
Melanoma | 2 | 2023 | 5719 | 0.110 |
Why?
|
Sulfonamides | 1 | 2024 | 1984 | 0.110 |
Why?
|
Endoplasmic Reticulum | 1 | 2020 | 1132 | 0.110 |
Why?
|
Pneumonectomy | 1 | 2021 | 1128 | 0.110 |
Why?
|
Leadership | 1 | 2023 | 1392 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 5 | 2024 | 5696 | 0.110 |
Why?
|
Medicare Part C | 1 | 2019 | 335 | 0.110 |
Why?
|
Pyrazoles | 2 | 2024 | 2033 | 0.110 |
Why?
|
Disease Progression | 3 | 2022 | 13632 | 0.110 |
Why?
|
Intestine, Small | 1 | 2019 | 1214 | 0.100 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 1884 | 0.100 |
Why?
|
DNA-Binding Proteins | 2 | 2021 | 9601 | 0.100 |
Why?
|
Paclitaxel | 1 | 2020 | 1728 | 0.100 |
Why?
|
Anal Canal | 3 | 2020 | 376 | 0.100 |
Why?
|
Tumor Burden | 1 | 2018 | 1885 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2021 | 1587 | 0.100 |
Why?
|
Carcinoma | 1 | 2023 | 2312 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1640 | 0.100 |
Why?
|
Professional-Patient Relations | 1 | 2017 | 721 | 0.100 |
Why?
|
Cohort Studies | 4 | 2023 | 41649 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2021 | 2880 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2017 | 995 | 0.090 |
Why?
|
Genomics | 2 | 2017 | 5929 | 0.090 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8041 | 0.090 |
Why?
|
Early Detection of Cancer | 2 | 2022 | 3236 | 0.090 |
Why?
|
Gastrointestinal Diseases | 1 | 2019 | 1203 | 0.090 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1490 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2022 | 2942 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 1 | 2020 | 2056 | 0.090 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3430 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 634 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 4 | 2025 | 6499 | 0.080 |
Why?
|
Biopsy | 2 | 2023 | 6763 | 0.080 |
Why?
|
California | 1 | 2013 | 1436 | 0.080 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 1643 | 0.080 |
Why?
|
Maximum Tolerated Dose | 2 | 2023 | 898 | 0.080 |
Why?
|
Microsatellite Instability | 2 | 2024 | 728 | 0.080 |
Why?
|
Health Care Surveys | 1 | 2016 | 2424 | 0.080 |
Why?
|
Tumor Microenvironment | 4 | 2024 | 3946 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4108 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 4348 | 0.070 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6547 | 0.070 |
Why?
|
Health Personnel | 2 | 2022 | 3390 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3513 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3413 | 0.070 |
Why?
|
Communication | 2 | 2022 | 3916 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2334 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4900 | 0.070 |
Why?
|
Terminal Care | 1 | 2018 | 1774 | 0.060 |
Why?
|
Health Status | 1 | 2019 | 4080 | 0.060 |
Why?
|
Health Expenditures | 1 | 2018 | 2387 | 0.060 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2018 | 2329 | 0.060 |
Why?
|
Mice, Nude | 2 | 2024 | 3618 | 0.060 |
Why?
|
Laparoscopy | 1 | 2017 | 2039 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2021 | 16047 | 0.060 |
Why?
|
Bayes Theorem | 2 | 2023 | 2354 | 0.060 |
Why?
|
Forkhead Transcription Factors | 2 | 2022 | 1624 | 0.060 |
Why?
|
Gallium Radioisotopes | 1 | 2024 | 195 | 0.050 |
Why?
|
Physicians | 1 | 2021 | 4588 | 0.050 |
Why?
|
Ultrasonography | 1 | 2017 | 5993 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14751 | 0.050 |
Why?
|
United States | 8 | 2024 | 72903 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2018 | 4300 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3925 | 0.050 |
Why?
|
Incidence | 1 | 2021 | 21480 | 0.050 |
Why?
|
Somatostatin | 1 | 2025 | 459 | 0.050 |
Why?
|
Genetic Testing | 1 | 2016 | 3595 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2019 | 9249 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2023 | 299 | 0.050 |
Why?
|
Septins | 1 | 2022 | 47 | 0.050 |
Why?
|
Radiotherapy Dosage | 2 | 2019 | 2865 | 0.050 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2023 | 332 | 0.050 |
Why?
|
MutS Homolog 2 Protein | 1 | 2022 | 200 | 0.050 |
Why?
|
Palliative Care | 1 | 2017 | 3645 | 0.050 |
Why?
|
Oximes | 1 | 2023 | 305 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 161 | 0.050 |
Why?
|
Risk | 1 | 2013 | 9591 | 0.050 |
Why?
|
Phenylurea Compounds | 1 | 2024 | 536 | 0.050 |
Why?
|
Risk Assessment | 1 | 2022 | 24282 | 0.050 |
Why?
|
GTP Phosphohydrolases | 1 | 2024 | 523 | 0.040 |
Why?
|
Lamivudine | 1 | 2022 | 368 | 0.040 |
Why?
|
Surge Capacity | 1 | 2020 | 48 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2019 | 3608 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 878 | 0.040 |
Why?
|
Retreatment | 1 | 2021 | 598 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5389 | 0.040 |
Why?
|
DNA | 2 | 2024 | 7202 | 0.040 |
Why?
|
Pancreatectomy | 1 | 2023 | 820 | 0.040 |
Why?
|
Mucins | 1 | 2022 | 567 | 0.040 |
Why?
|
Colostomy | 1 | 2019 | 107 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2024 | 39193 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 4058 | 0.040 |
Why?
|
Mitomycin | 1 | 2019 | 261 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 714 | 0.040 |
Why?
|
Risk Factors | 3 | 2020 | 74840 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12807 | 0.040 |
Why?
|
Esophagogastric Junction | 1 | 2020 | 351 | 0.040 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2019 | 212 | 0.040 |
Why?
|
Grief | 1 | 2020 | 255 | 0.040 |
Why?
|
Rwanda | 1 | 2020 | 672 | 0.040 |
Why?
|
Quinazolines | 1 | 2024 | 1364 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 862 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2020 | 15747 | 0.040 |
Why?
|
India | 1 | 2024 | 2334 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2018 | 9071 | 0.030 |
Why?
|
Fibrosis | 1 | 2024 | 2070 | 0.030 |
Why?
|
Registries | 1 | 2013 | 8297 | 0.030 |
Why?
|
Sex Factors | 2 | 2021 | 10603 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2024 | 36532 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8733 | 0.030 |
Why?
|
Vulnerable Populations | 1 | 2012 | 718 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2020 | 561 | 0.030 |
Why?
|
Young Adult | 2 | 2020 | 59889 | 0.030 |
Why?
|
Tumor Escape | 1 | 2019 | 371 | 0.030 |
Why?
|
Propensity Score | 1 | 2023 | 1968 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2020 | 811 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2019 | 493 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2019 | 1837 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2024 | 17075 | 0.030 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2020 | 1151 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2417 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2024 | 2699 | 0.030 |
Why?
|
Health Services Accessibility | 2 | 2022 | 5508 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2020 | 2505 | 0.030 |
Why?
|
Age Factors | 2 | 2023 | 18380 | 0.030 |
Why?
|
Mice, SCID | 1 | 2019 | 2630 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2022 | 3602 | 0.030 |
Why?
|
Models, Economic | 1 | 2018 | 716 | 0.030 |
Why?
|
Hepatectomy | 1 | 2017 | 589 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 927 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5370 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2017 | 20659 | 0.030 |
Why?
|
SEER Program | 1 | 2018 | 1446 | 0.030 |
Why?
|
Animals | 5 | 2024 | 168764 | 0.030 |
Why?
|
Pyridines | 1 | 2024 | 2888 | 0.020 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1365 | 0.020 |
Why?
|
RNA | 1 | 2022 | 2717 | 0.020 |
Why?
|
Administration, Oral | 1 | 2020 | 4015 | 0.020 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2018 | 784 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 6113 | 0.020 |
Why?
|
Mice | 3 | 2024 | 81819 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2741 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2023 | 10729 | 0.020 |
Why?
|
Disease Management | 1 | 2021 | 2535 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 2887 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2900 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3050 | 0.020 |
Why?
|
Boston | 1 | 2012 | 9338 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3910 | 0.020 |
Why?
|
Patient Care Team | 1 | 2020 | 2517 | 0.020 |
Why?
|
Recurrence | 1 | 2021 | 8501 | 0.020 |
Why?
|
Proteins | 1 | 2023 | 5995 | 0.020 |
Why?
|
Population Surveillance | 1 | 2019 | 2590 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2022 | 11022 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2018 | 2589 | 0.020 |
Why?
|
Hospitals | 1 | 2022 | 3888 | 0.020 |
Why?
|
Education, Medical | 1 | 2020 | 1746 | 0.020 |
Why?
|
Linear Models | 1 | 2018 | 5876 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8875 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10383 | 0.020 |
Why?
|
Mass Screening | 1 | 2012 | 5446 | 0.020 |
Why?
|
Adolescent | 2 | 2024 | 88835 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15398 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12976 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12056 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 12509 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2020 | 7851 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10850 | 0.010 |
Why?
|
Signal Transduction | 1 | 2020 | 23601 | 0.010 |
Why?
|